The DOI matches its Crossref record; 46 of the 49 references it cites were found in a registry or an index.
Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece
Abstract
Aim The present study aimed to validate the Finnish Type 2 Diabetes Risk Score (FINDRISC) questionnaire for its ability to predict the presence of any glucose homoeostasis abnormalities and the metabolic syndrome (MetS) in the Greek population. Methods Validation was performed on a sample of individuals who had agreed to participate in a screening program for type 2 diabetes (T2D) prevention (the Greek part of the DE-PLAN study), using both FINDRISC and oral glucose tolerance tests (OGTT). Impaired fasting glucose (IFG) was defined as a fasting plasma glucose level of 6.1-6.9 mmol/L, and impaired glucose tolerance (IGT) as a 2-h plasma glucose of 7.8-11.0 mmol/L. The predictive value of the FINDRISC was cross-sectionally evaluated using the area under the receiver operating characteristic (AUROC) curve method. Results A total of 869 individuals (379 men, aged 56.2 ± 10.8 years) were screened from the general population living in the city and suburbs of Athens. OGTT revealed the presence of unknown diabetes in 94 cases (10.8%), IFG in 85 (9.8%) and IGT in 109 (12.6%). The sensitivity of a FINDRISC score greater or equal to 15 (45% of the population) to predict unknown diabetes was 81.9% and its specificity was 59.7%. The AUROC curve for detecting unknown diabetes was 0.724 (95% CI: 0.677-0.770). For any dysglycaemia, the AUROC curve was 0.716 (0.680-0.752) while, for detection of the MetS, it was 0.733 (0.699-0.767). Conclusion The FINDRISC questionnaire performed well as a sc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, FINDRISC is the most commonly evaluated diabetes risk score worldwide [17,18,19,20,21,22,23,24,25] and has been recommended as the best available risk assessment tool for use in the clinical practice by a systematic review [11].”
From A Novel Testing Model for Opportunistic Screening of Pre-Diabetes and Diabetes among U.S. Adults (2015) · cites this paper as [19]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 14,094
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“[3] Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, IlanneParikka P, et al.”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Lindström, J., & Tuomilehto, J. O. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.725 · Cited by 1,937
Cited by
Sorted by citations
Diabetes Mellitus: Screening and Diagnosis.
Pippitt, K. A., Li, M., & Gurgle, H. E. (2016) · PubMed · Cited by 153
Zhang, L., Zhang, Z., Zhang, Y., Hu, G., & Chen, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097865 · Cited by 130
Jiménez-Lucena, R., Rangel-Zúñiga, O. A., Alcala-Diaz, J. F., López-Moreno, J., Roncero‐Ramos, I., Molina‐Abril, H., Yubero‐Serrano, E. M., Caballero‐Villarraso, J., Delgado‐Lista, J., Castano, J. P., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.002 · Cited by 121
Costa, B., Barrio, F., Piñol, J. L., Cabré, J.-J., Mundet, X., Sagarra-Alamo, R., Salas‐Salvadó, J., & Solà-Morales, O. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-45 · Cited by 71
Gómez-Arbeláez, D. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i17.1337 · Cited by 64
Metadata
- Authors
- Makrilakis, K., Liatis, S., Grammatikou, S., Perrea, D., Stathi, C., Tsiligros, P., & Katsilambros, N.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Makrilakis, K.
- Venue
- Diabetes & Metabolism
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 37
- Issue
- 2
- Pages
- 144-151
- ISSN
- 1262-3636 (ISSN-L)
- OpenAlex
- W2061002349
- Cited by
- 199
- References
- 49
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 17 · 2020: 25 · 2019: 9 · 2018: 13 · 2017: 10 · 2016: 18 · 2015: 14 · 2014: 10 · 2013: 11 · 2012: 5
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- FINDRISC questionnaire, type 2 diabetes prediction, undiagnosed type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, metabolic syndrome, diabetes screening, Greek population, questionnaire validation, oral glucose tolerance test, Athens, Greece, cross-cultural adaptation, sensitivity and specificity
- MeSH terms
- Adult, Aged, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Fasting, Female, Finland, Glucose Tolerance Test, Greece, Humans, Male, Mass Screening, Middle Aged, Surveys and Questionnaires, Risk Factors, ROC Curve, Metabolic Syndrome, Glucose Metabolism Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
